Dianthus (DNTH) Gains 18% in the Past Month: Here's Why [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
Its lead investigational candidate is DNTH103, which is being developed for several autoimmune indications, like generalized Myasthenia Gravis (gMG), multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyneuropathy (CIDP). Dianthus' stock gained 17.5% in the past month after the company announced the FDA clearance of its investigational new drug application to begin a phase II study called MoMeNtum of DNTH103 in patients with MMN, around mid-June. MMN is a rare, progressive neurological disorder characterized by muscle weakness and wasting in the limbs due to immune system attacks on motor nerves. DNTH103 is a monoclonal antibody in clinical development. It is designed to selectively inhibit the active form of the C1s protein, a vital component of the classical complement pathway, which has been clinically validated as a therapeutic target for autoimmune diseases. Dianthus believes the investigational candidate has best-in-class potential across various aut
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.MarketBeat
- Immunovant stock falls 8% amid Graves' disease program update Sep. 09, 2024 5:18 PM ET By: Val Brickates Kennedy , SA News Editor [Seeking Alpha]Seeking Alpha
- Immunovant, Inc. (NASDAQ: IMVT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? [Yahoo! Finance]Yahoo! Finance
- IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab [Yahoo! Finance]Yahoo! Finance
IMVT
Earnings
- 8/6/24 - Miss
IMVT
Sec Filings
- 9/9/24 - Form 8-K
- 8/23/24 - Form 4
- 8/23/24 - Form 4
- IMVT's page on the SEC website